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Mu opioid receptor (MOR) agonists are widely used
for the treatment of pain; however, chronic use
results in the development of tolerance and depen-
dence. It has been demonstrated that coadministra-
tion of a MOR agonist with a delta opioid receptor
(DOR) antagonist maintains the analgesia associ-
ated with MOR agonists, but with reduced negative
side-effects. Using our newly refined opioid recep-
tor models for structure-based ligand design, we
have synthesized several pentapeptides with tai-
lored affinity and efficacy profiles. In particular, we
have obtained pentapeptides 8, Tyr-c(S-S)[DCys-
1Nal-Nle-Cys]NH2, and 12, Tyr-c(S-S)[DCys-1Nal-
Nle-Cys]OH, which demonstrates high affinity and
full agonist behavior at MOR, high affinity but very
low efficacy for DOR, and minimal affinity for the
kappa opioid receptor (KOR). Functional properties
of these peptides as MOR agonists ⁄ DOR antago-
nists lacking undesired KOR activity make them
promising candidates for future in vivo studies of
MOR ⁄ DOR interactions. Subtle structural variation
of 12, by substituting D-Cys5 for L-Cys5, generated
analog 13, which maintains low nanomolar MOR
and DOR affinity, but which displays no efficacy at
either receptor. These results demonstrate the
power and utility of accurate receptor models for
structure-based ligand design, as well as the
profound sensitivity of ligand function on its
structure.
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The recognition that a specific receptor often plays a pivotal role in
a disease state shifted the drug discovery paradigm toward a 'one
disease, one target' approach. The driving force behind this shift
was the idea that the more specific a drug, the fewer negative
side-effects it will elicit. Recently, however, it has been recognized
that the simultaneous modulation of multiple targets may generate
a more desirable drug profile, in some cases even reducing the
development of negative side-effects (1,2). This concept is illus-
trated in the field of opioid analgesics, where the coadministration
of a mu opioid receptor (MOR) agonist with a delta opioid receptor
(DOR) antagonist provides all the expected analgesia of a MOR
agonist, but with reduced negative side-effects, such as constipa-
tion and respiratory depression, and more interestingly, reduced tol-
erance and dependence liabilities (3–7), features that limit the
clinical use of opioid analgesics (8).
Our laboratory and others (6–18) have explored the development of
mixed efficacy ligands where MOR agonist activity is combined with
DOR antagonism in the same molecule using a 'merged' pharmaco-
phore (2). Such a multifunctional ligand would possess considerable
advantages over the traditional approach of using a combination of
selective opioid drugs with possibly differing pharmacokinetic or
pharmacodynamic properties. Peptides provide a convenient starting
point for the development of multifunctional opioid ligands. Many
endogenous and synthetic opioid peptide ligands have been studied
and their SAR has been well characterized, providing the foundation
for applying rational design to existing structures to explore the
MOR and DOR binding pockets.
Previous work in our laboratory resulted in lead peptide 1 (Tyr-c(S-
S)[DCys-Phe-Phe-Cys]NH2) (19), which displays full agonism at MOR
and slightly reduced efficacy at DOR as well as high affinity for
both receptors (Table 1). Because 1 has appreciable DOR efficacy,
we then focused our efforts on designing ligands that retain MOR
agonist activity, but with reduced DOR efficacy (6). Using our
receptor models for both active and inactive states of MOR and
DOR (6,8,20–24), we predicted that adding bulky aromatic substitu-
ents in the third or fourth position of peptide 1 would produce a
steric clash in the DOR active state binding site, which would not
be seen in the DOR inactive site, thus favoring binding to the
DOR inactive state and consequently resulting in lower DOR effi-
cacy (6). Docking to corresponding active and inactive state MOR
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models revealed no analogous receptor state-specific adverse inter-
actions; we therefore predicted that increasing steric bulk at posi-
tion 3 or 4 would provide the desired MOR agonist ⁄ DOR
antagonist profile. Incorporation of 1-Nal (1-naphthylalanine) or 2-
Nal (2-naphthylalanine) into position 3 or 4 of 1 did indeed yield
analogs with high MOR ⁄ low DOR efficacy, but all analogs also
retained high KOR affinity (6). Such KOR activity is less desirable;
while KOR agonists are known to provide some analgesic proper-
ties, they are also known to cause dysphoria, which severely limits
their usefulness (25). This study makes further use of our recep-
tor–ligand models to design analogs that maintain high affinity for




All reagents and solvents were purchased from commercial sources
and used without further purification. All chemicals and biochemi-
cals were purchased from Sigma Aldrich (St. Louis, MO, USA) or
Fisher Scientific (Hudson, NH, USA), unless otherwise noted. All tis-
sue culture reagents were purchased from Gibco Life Sciences
(Grand Island, NY, USA). Radioactive compounds were purchased
from Perkin-Elmer (Waltham, MA, USA). Peptide synthesis reagents,
amino acids, and Rink resin were purchased from Advanced Chem
Tech (Louisville, KY, USA). Wang resins were purchased from Nova
Biochem, EMD (Gibbstown, NJ, USA).
Solid-phase peptide synthesis
Peptides were synthesized using standard solid-phase Fmoc (fluore-
nylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Syn-
thesizer (CS Bio Company, Menlo Park, CA, USA), using previously
described protocols (26). C-terminal amide peptides were synthe-
sized using Rink resin, C-terminal acid peptides were synthesized
using Fmoc–Wang resin preloaded with the C-terminal amino acid.
A 20% solution of piperidine in N-methyl-2-pyrrolidone (NMP) was
used to remove the first Fmoc-protecting group before synthesis
and again to remove the Fmoc-protecting group after each coupling
cycle. Coupling was performed using a fourfold excess of amino
acid and a solution of 0.4 M hydroxybenzotriazole (HOBt) and O-ben-
zotriazole-N, N, N¢, N¢-tetramethyl-uroniumhexafluoro-phosphate
(HBTU) in dimethylformamide (DMF), in the presence of diisopropyl-
ethylamine (DIEA). After the synthesis was complete, the resin was
washed with NMP, then with dichloromethane, and dried under vac-
uum. The peptides were cleaved from the resin and side-chain-pro-
tecting groups removed by treatment at room temperature for 2 h
with a cleavage cocktail consisting of 9.5 mL trifluoroacetic (TFA)
acid, 0.25 mL triisopropylsilane (TIS), and 0.25 mL H2O. The solution
was concentrated in vacuo, and peptides were precipitated using
cold, fresh diethylether. The filtered crude material was then puri-
fied using a Waters semipreparative HPLC (Waters Corporation, Mil-
ford, MA, USA) with a Vydac Protein and Peptide C18 column,
using a linear gradient 10% solvent B (0.1% TFA acid in acetoni-
trile) in solvent A (0.1% TFA acid in water) to 60% solvent B in sol-
vent A, at a rate of 1% per minute. The identity of all peptides
were determined using ESI-MS performed on an Agilent Technolo-
gies LC ⁄ MS system using a 1200 Series LC and 6130 Quadrupole
LC ⁄ MS (Agilent Technologies, Santa Clara, CA, USA) in positive
mode with 50–100 lL injection volume and a linear gradient of 0%
solvent D (0.02% TFA and 0.1% acetic acid (AcOH) in acetonitrile)
in solvent C (0.02% TFA and 0.1% AcOH in water) to 60% solvent
D in solvent C in 15 min. The purity of all peptides was determined
using a Waters Alliance 2690 Analytical HPLC (Waters Corporation)
and Vydac Protein and Peptide C18 reverse phase column, using a
linear gradient of 0–70% solvent B in solvent A at a rate of 1%
per minute. Linear peptides were purified to ‡95% purity by UV
absorbance at 230 nm.
Disulfide cyclization of linear peptides
Pure linear disulfhydryl-containing peptide was dissolved at
1mg ⁄ mL in argon saturated solution of 1% (v ⁄ v) AcOH in H2O at
4C. The pH of the peptide solution was raised to 8.5 using
NH4OH, followed by the addition of 4 molar equivalents of
K3Fe(CN)6. The reaction mixture was stirred on ice, under argon
for two minutes and quenched by addition of glacial acetic acid
to pH 3.5. The reaction mixture was incubated with 100–200
mesh anion exchange resin AG-3-X4 (Biorad, Hercules, CA, USA)
and swirled occasionally at room temperature until the solution
was colorless. The crude mixture was then filtered, concentrated
in vacuo, and purified to ‡98% purity as determined by UV absor-
bance at 230 nm as described earlier to yield the disulfide linked
Table 1: Binding Affinities and Efficacies of Peptides 1–5
Peptide Sequence
Ki (nM) Efficacy (% standard)
MOR DOR KOR MOR DOR KOR
1 Tyr-c(S-S)[DCys-Phe-Phe-Cys]NH2 0.27 € 0.2 0.8 € 0.3 8.6 € 0.5 77 € 9 69 € 1.6 74 € 17
2 Tyr-c(S-S)[DCys-Phe-Leu-Cys]NH2 1.3 € 0.7 2.0 € 0.8 3100 € 890 100 € 2 74 € 13 dns
3 Tyr-c(S-S)[DCys-Phe-Ile-Cys]NH2 1.5 € 0.7 0.3 € 0.2 980 € 310 93 € 4 86 € 7 dns
4 Tyr-c(S-S)[DCys-Phe-Nle-Cys]NH2 1.6 € 0.1 1.7 € 0.3 2600 € 130 104 € 10 103 € 1.5 nt
5 Tyr-c(S-S)[DCys-Phe-Nle-DCys]NH2 0.62 € 0.1 1.3 € 0.4 210 € 230 64 € 6 47 € 9.3 nt
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] diprenorphine. Efficacy data were obtained using [35S] GTPcS binding
assay. Efficacy is represented as per cent maximal stimulation relative to standard agonists DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 lM concen-
trations. All values are expressed as mean € SEM of three separate assays performed in duplicate. Cyclization abbreviated as S-S for disulfide linkage, nt = not
tested, dns = does not stimulate.
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cyclized peptides. The identity of cyclic peptides was determined
by ESI-MS as described earlier.
Dithioether cyclization of linear peptides
A DMF solution of the linear peptide (15 mg ⁄ 40 mL) containing 5
molar equivalents of 1,2-dibromoethane was added dropwise to a
round-bottom flask containing 10 molar equivalents of potassium
tert-butoxide in 100 mL of anhydrous DMF saturated with argon, on
ice. The reaction was stirred for 2 h under argon, on ice, and then
quenched to pH 3.5 with glacial acetic acid. Solvents were removed
in vacuo, and the residue was purified to ‡98% purity as deter-
mined by UV absorbance at 230 nm as described earlier to afford
the alkyl dithioether cyclized peptide. The identity of cyclic peptides
was determined by ESI-MS as described earlier.
Cell lines and membrane preparations
C6-rat glioma cells stably transfected with a rat l (C6-MOR) or rat
d (C6-DOR) opioid receptor (27) and Chinese hamster ovary (CHO)
cells stably expressing a human j (CHO-KOR) opioid receptor (28)
were used for all in vitro assays. Cells were grown to confluence
at 37 C in 5% CO2 in Dulbecco's modified Eagle's medium contain-
ing 10% fetal bovine serum and 5% penicillin ⁄ streptomycin. Mem-
branes were prepared by washing confluent cells three times with
ice-cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4,
0.38 mM KH2PO4, pH 7.4). Cells were detached from the plates by
incubation in warm harvesting buffer (20 mM HEPES, 150 mM NaCl,
0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200 · g
for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris-HCl
buffer, pH 7.4 and homogenized with a Tissue Tearor (Biospec Prod-
ucts, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The homoge-
nate was centrifuged at 20 000 · g for 20 min at 4 C, and the
pellet was rehomogenized in 50 mM Tris-HCl with a Tissue Tearor
for 10 s at setting 2, followed by recentrifugation. The final pellet
was resuspended in 50 mM Tris-HCl and frozen in aliquots at
)80 C. Protein concentration was determined via Bradford assay
using bovine serum albumin as the standard.
Radioligand binding assays
Opioid ligand-binding assays were performed using competitive
displacement of 0.2 nM [3H]diprenorphine (250 lCi, 1.85TBq ⁄ mmol)
by the test compound from membrane preparations containing opi-
oid receptors. The assay mixture, containing membrane suspension
(20 lg protein ⁄ tube) in 50 mM Tris-HCl buffer (pH 7.4), [3H]dipr-
enorphine, and various concentrations of test peptide, was incu-
bated at room temperature for 1 h to allow binding to reach
equilibrium. The samples were rapidly filtered through Whatman
GF ⁄ C filters using a Brandel harvester (Brandel, Gaithersburg, MD,
USA) and washed three times with 50 mM Tris-HCl buffer. The
radioactivity retained on dried filters was determined by liquid
scintillation counting after saturation with EcoLume liquid scintilla-
tion cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer; Waltham).
Nonspecific binding was determined using 10 lM naloxone. Ki val-
ues were calculated using nonlinear regression analysis to fit a
logistic equation to the competition data using GRAPHPAD PRISM ver-
sion 5.01 for Windows (GraphPad Software Inc., La Jolla, CA,
USA). The results presented are the mean € standard error from
at least three separate assays performed in duplicate.
Stimulation of [35S]GTPcS Binding
Agonist stimulation of [35S] guanosine 5¢-O-[gamma-thio]triphos-
phate ([35S]GTPcS, 1250 Ci, 46.2TBq ⁄ mmol) binding was measured
as described previously (29). Briefly, membranes (10–20 lg of pro-
tein ⁄ tube) were incubated 1 h at room temperature in GTPcS buffer
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing
0.1 nM [35S]GTPcS, 100 lM guanosine diphosphate (GDP), and vary-
ing concentrations of test peptides. Peptide stimulation of
[35S]GTPcS was compared with 10 lM standard compounds [D-Ala2,
N-MePhe4, Gly-ol]-enkephalin (DAMGO) at MOR, D-Pen2,5- enkepha-
lin (DPDPE) at DOR, or U69,593 at KOR. The reaction was termi-
nated by rapidly filtering through GF ⁄ C filters and washing ten
times with GTPcS buffer, and retained radioactivity was measured
as described earlier. The results presented are the mean € standard
error from at least three separate assays performed in duplicate;
maximal stimulation was determined using nonlinear regression
analysis with GRAPHPAD PRISM.
Determination of Ke through stimulation of
[35S]GTPcS Binding
Agonist stimulation of [35S] guanosine 5¢-O-[gamma-thio]triphos-
phate ([35S]GTPcS, 1250 Ci, 46.2TBq ⁄ mmol) binding was measured
for known agonists, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)
at MOR and D-Pen2,5- enkephalin (DPDPE) at DOR, as described ear-
lier. Control wells contained only membranes (10–20 lg of pro-
tein ⁄ tube) GTPcS buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM
MgCl2, pH 7.4) containing 0.1 nM [
35S]GTPcS, 100 lM guanosine
diphosphate (GDP), and varying concentrations of known agonists.
Test wells contained all of the same components as the control
wells, as well as a constant concentration of the test antagonist.
The assay mixture was incubated for 1 h at room temperature and
was terminated by rapidly filtering through GF ⁄ C filters and wash-
ing ten times with GTPcS buffer. Retained radioactivity was mea-
sured as described earlier. The results presented are the
mean € standard error from at least three separate assays per-
formed in duplicate; EC50 values were determined using nonlinear
regression analysis with GRAPHPAD PRISM and Ke values calculated
based of these EC50 values.
Receptor modeling
The homology modeling of opioid receptors in complexes with pep-
tide ligands was performed as previously described (6,8,19,30). The
procedure included the following steps: (i) residue substitution in
corresponding structural template(s); (ii) rigid body helix movement
to reproduce structural rearrangement during receptor activation
observed in crystal structures of rhodopsin and adrenergic receptor
(31); (iii) peptide ligand docking in accordance with mutagenesis-
derived constraints; and (iv) refinement of receptor–ligand complex
using distance geometry and energy minimization with CHARMm.
The validity of this modeling procedure has been assessed in blind
prediction experiments of structural modeling of MOR (6,8), A2a-
adenosine receptor (32), CXCR4, and D3 dopamine receptor (30)
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performed before the release of the corresponding crystal struc-
tures. The following comparison with experimental structures
showed relatively high accuracy of our homology models: rmsd
were between 1.5 and 2.5  for seven transmembrane helices
(30,32). A comparison of our previously developed opioid receptor
models (6,8,24,33) and recently released crystal structures of the
mouse MOR (34) and the human KOR (35) demonstrated the high
reliability in prediction of ligand–receptor interactions in the more
conserved 'message' region located deeply in the ligand binding
pocket, and less precise modeling in the 'address' region of flexible
extracellular loops, which are responsible for ligand selectivity.
Despite some inaccuracies, the previous models suggested the
important role of interactions between Met199 and Trp284 of DOR
and pentapeptide Phe3 and Phe4 side chains, respectively, and aro-
matic interactions between pentapeptide Phe4 side chain and resi-
dues from the extracellular loop 2 (6,7,24,33).
For this study, we used X-ray structures of the mouse MOR (PDB
ID: 4dkl) and the human KOR (PDB ID: 4djh) as inactive receptor
conformations for docking peptide ligands in a mode similar to that
of co-crystalized antagonists. To minimize steric hindrances, manual
docking of peptides in low-energy conformations was followed by
the automated rigid docking implemented in QUANTA (Accelrys Inc).
The MOR crystal structure was also used to generate the homology
model of the inactive conformation of the human DOR (UniProt ID:
P41143, residues 46–333). The comparison of this DOR model with
the experimental structure of the mouse DOR (PDB ID: 4ej4) (36)
released after manuscript submission demonstrates their close
resemblance (rmsd 1.16  for 249 Ca-atoms) in all regions except
some parts of extracellular loops 2 and 3 (residues 192–195, 288–
295). In the experimental DOR, structure residues Asp290–Arg291 of
the extracellular loop 3 appear to be located deeper in the binding
pocket than we anticipated, thus forming additional contacts with
the variable 'address' region of peptides. However, the shift of this
loop does not alter essential interactions between the common
'message' region of cyclic peptides and receptor residues, which
has been previously suggested based on our and other mutagenesis
data (18,19). These interactions included hydrogen-bonding between
peptide N+ and Asp from TM3 (Asp128 in DOR), water-mediated
hydrogen-bonding between OH-group of peptide Tyr1 and His from
TM6 (His278 in DOR), aromatic interactions between Tyr1 of peptide
and Tyr from TM3 (Tyr129 in DOR), and interactions of the disulfide
bridge of the peptide with TM6 (Val281 in DOR).
Further, we used the crystal structure of the human KOR (PDB ID:
4djh) together with our previous active state models (6,8) for model-
ing of the active conformations of the mouse MOR using the proce-
dure described earlier. The KOR structure was chosen as a
modeling template because it demonstrates some inward movement
of the extracellular ends of TMs 2, 5, 6, and 7 and the outward
shift of TM3, as compared to other opioid receptor structures (PDB
IDs: 4dkl, 4ej4). Similar helix movements were attributed to the
activated receptor conformation (31). However, although the experi-
mental KOR structure shows some active-like rearrangements in the
extracellular region, it does not reproduce the main characteristic
feature of the activated receptors in the intracellular part – the
TM6 rotation and the large shift of its N-terminus away from TM3
and closer to TM5 along with the shift of the end of TM7 toward
TM2 (31). To reproduce these large relocations of intracellular ends
of TMs 5, 6, and 7 associated with receptor activation, we used
constraints from our previous models of the active receptor confor-
mations (6,8). The thus obtained model of the activated MOR after
energy refinement was used as a template for modeling of the
active states of KOR and DOR using residue substitution followed
by energy minimization. These models of the opioid receptor active
conformations were used for docking high efficacy peptide ligands.
Low-energy conformations of cyclic pentapeptides were generated
using previously developed pharmacophore models of tetrapeptides
(37) with additional conformational search in the region of the fifth
residue and disulfide bridge. Co-ordinates of MOR (active and inac-
tive states), DOR (inactive state), and KOR (active state) with pep-
tide 1 can be downloaded from our website (http://
mosberglab.phar.umich.edu/resources/).
Results and Discussion
To understand the basis for the relatively high KOR binding affinity
of 1 and related compounds in the series (19), we docked 1 to our
previously developed active state model of KOR (24,33). The docking
suggested an important role of Phe4 of peptide 1 in interacting
with KOR. An improved active state model generated from the
recently released crystal structure of KOR (35) demonstrates that
Phe4 of 1 indeed can form p-stacking interactions with Tyr219 from
extracellular loop 2 located at the beginning of helix 5 (Figure 1).
These interactions likely contribute to the binding and agonist char-
acter of peptide 1. DOR and MOR lack a corresponding aromatic
residue in the binding site – DOR has a Ser206 and MOR has a
Thr225 in the analogous position. We hypothesized that changing
the Phe4 of peptide 1 to a nonaromatic residue would eliminate
this favorable aromatic interaction with Tyr219 and thus decrease
affinity to KOR. As shown in Table 1, replacing Phe4 of peptide 1
with the aliphatic residues Leu, Ile, or Nle, in peptides 2 through 4
resulted in the predicted decreased binding to KOR (Table 1).
Figure 1: Modeling of peptide 1 (Tyr-c(S-S)[DCys-Phe-Phe-
Cys]NH2) docked in the KOR active state model. Highlighted is the
p–p interaction between Phe4 of 1 with Tyr219 of KOR (shown by
dots). This favorable interaction appears to contribute to the high
affinity of 1 for KOR as well as its agonist character.
Anand et al.
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As all three analogs with an aliphatic residue in position 4 dis-
played similar opioid profiles, high affinity and efficacy for MOR
and DOR with low KOR activity, for convenience, we chose to carry
forward with analogs containing the Nle4 substitution. Because cyc-
lic opioid pentapeptides with either D- or L-stereochemistry in resi-
due 5 displayed similar MOR and DOR affinities in the initial
examples of this series (19), we also examined the opioid profile of
5, the D-Cys5 diastereomer of 4. This analog displayed a similar
binding profile as 4, but with somewhat reduced efficacy at both
MOR and DOR (Table 1). Thus, we chose both 4 and 5 as starting
points for modifications to reduce DOR efficacy.
To achieve this, we again relied on our previously described recep-
tor models (6,8,20–24), which suggested that bulkier aromatic side
chains replacing Phe3 or Phe4 of the ligands would better fit the
large and more open antagonist binding pocket of the receptors in
the inactive state, while having steric clashes in the more narrow
agonist binding pocket of the active receptor conformation. A
greater effect was expected for DOR, which has more bulky resi-
dues, Lys108, Met199, and Trp284, occluding the ligand binding pocket
than MOR, with Asn127, Thr218, and Lys303 at the corresponding
positions. Examination of our current, refined models of DOR and
MOR in complex with 1 supported our previous suggestions (Fig-
ure 2). Of particular importance, here is the observation that Phe3
of peptide 1 is in close proximity to Met199 in the DOR agonist
binding pocket (Figure 2A). However, in the DOR antagonist binding
site (Figure 2B), Met199 is angled away from the ligand, enlarging
the binding pocket. Replacing the Phe3 of peptide 1 with a larger
residue would be expected to increase the steric clash between the
ligand and the active conformation of DOR, disfavoring the binding
of the ligand to the active conformation and thus reducing its ago-
nist efficacy, as we have observed before (8). However, because of
the presence of the smaller side chain of Thr218 in the MOR binding
pocket (Figure 2C) instead of Met199 in the DOR binding pocket,
adding steric bulk in the 3 position of peptide 1 should have less
effect on MOR efficacy. Consequently, we prepared and pharmaco-
logically assessed a series of pentapeptides based on 4 and 5, in
which the Phe3 residue was replaced by 1-Nal or 2-Nal (Table 2).
Peptides 6–9 represent the 1-Nal3 and 2-Nal3 analogs of 4 and 5.
As seen in Table 2, replacing the Phe3 of 4 or 5 with 2-Nal (ana-
logs 6 and 7, respectively) greatly reduces efficacy at both MOR
and DOR, consistent with our earlier observations (6), while also
greatly reducing affinity at DOR. By contrast, the 1-Nal3 analogs 8
and 9 display a more promising profile in which DOR efficacy is
more selectively affected and DOR affinity is less drastically
reduced. In analogs 6–9, the D-Cys5 diastereomer exhibits a
greater ability to reduce efficacy than the corresponding L-Cys5, but
this effect is equally expressed at MOR and DOR.
In compounds 10 and 11, we examined the effect of increasing
the ring size of the 14-membered disulfide scaffold of 8 and 9 to a
16-membered ethylene dithioether-containing cycle, an approach we
have often used to modulate opioid activity (6,19,33). In the present
case, increasing the cycle size had little effect on binding affinity or
efficacy, with the exception of a rather large reduction in maximal
stimulation at MOR (51% versus 100% stimulation relative to the
standard, DAMGO) and a slight increase in KOR affinity displayed
by 10 compared to 8.
Among peptides 6–11, the most promising is 8 that possesses
high MOR affinity, full agonist behavior at MOR and greatly reduced
DOR efficacy (22% of DOR standard DPDPE). However, 8 displays
18-fold lower affinity at DOR compared with MOR. Furthermore,
A B
C D
Figure 2: Modeling of peptide
1 (Tyr-c(S-S)[DCys-Phe-Phe-Cys]NH2)
docked in the active and inactive
state models of DOR (A and B) and
MOR (C and D). Docking of 1 to
the active state of DOR shows a
steric clash between Phe3 of 1
and Met199 of DOR, highlighted by
an arrow in 2A; this steric clash is
not seen when 1 is docked in the
DOR inactive state binding site or
the MOR active or inactive state
binding sites.
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8 lacks the undesired KOR activity, which make it a promising
ligand for the exploration of functional MOR ⁄ DOR interactions.
Peptides 12–15, the C-terminal carboxylic acid counterparts of the
carboxamide terminal 8–11, were designed to restore a balance in
MOR and DOR affinity, because negatively charged C-terminal
groups often interfere with MOR binding (38). As seen in Table 2,
the carboxy-terminal analogs displayed the expected decrease in
MOR affinity, decreased KOR affinity, but little significant effect on
DOR binding. Peptide 13 was an exception, in that DOR affinity
improved approximately 13-fold compared with 9 (Ki = 4 versus
56 nM). Both disulfide-containing C-terminal carboxylic acids, 12
and 13, display the desired binding profile: high affinity for MOR
and DOR, low affinity for KOR. The dithioether-containing analogs,
14 and 15, have less desirable binding profiles displaying some-
what lower and ⁄ or less balanced MOR and DOR affinity and
reduced MOR efficacy.
Examination of the efficacy profiles of 12 and 13 reveals an inter-
esting observation. While 12, like its carboxamide terminal counter-
part 8, is a full agonist at MOR, with low partial DOR agonism
(20% maximal stimulation versus DPDPE), peptide 13, which dif-
fers from 12 only in the stereochemistry of the C-terminal Cys, acts
as an antagonist at both MOR and DOR. The functional antagonist
properties of 13 were confirmed by examining its effect on stimula-
tion of GTPcS binding of MOR by DAMGO and of DOR by DPDPE.
In both cases, 13 shifted the dose–response curve of the standard
ligand with Ke values of 2.13 € 0.64 and 20.3 € 6.3 nM for DAMGO
and DPDPE, respectively. Reduced efficacy of D-Cys5 versus L-Cys5-
containing analogs is a consistent feature among the compounds
shown in Table 2; however, the complete elimination of MOR effi-
cacy for 13 was unexpected. An explanation for this behavior can
be deduced from examination of 12 and 13 docked to the active
and inactive states of MOR. Figure 3A depicts 12 bound to our
model of the MOR active receptor. In this model, the C-terminal
COO- of 12, while being close to Glu229 from transmembrane helix
5, may also form an ionic bridge with the positively charged side
chain of Lys303 from helix 6. This ionic bridge can be formed only in
MOR and only in the active conformation, but not in DOR or KOR,
which have Trp284 (DOR) or Glu297 (KOR) in the corresponding posi-
tion in helix 6. The favorable ionic interactions of 12 in the agonist
binding pocket of MOR may explain its behavior as an efficacious
MOR agonist. The unfavorable ionic interaction between the C-ter-
minal carboxylate of 12 and Glu229 from helix 5 in MOR or Glu297
from helix 6 in KOR is consistent with the six and sevenfold
decreased affinity of 12 to MOR and KOR, respectively, as com-
pared to 8 with a C-terminal amide. For 13, the change in stereo-
chemistry of residue 5 orients the terminal COO- away from Lys303
and toward Glu229, resulting in an unfavorable ionic repulsion. How-
ever, in the inactive conformation of MOR (Figure 3B), rotation of
Glu229 and Lys233 relieves this repulsion. In the DOR models, the C-
terminus of 13 is close to the Asp210–Lys214 pair from helix 5 and
can form favorable ionic interactions with Lys214 in the inactive
receptor conformation. These ligand–receptor interactions help
explain the antagonist activity of 13 in MOR and its improved bind-
ing and antagonist activity at DOR.
Conclusions
The studies discussed in this article were aimed toward developing
opioid ligands that display high affinity and efficacy for MOR, high
affinity and low efficacy for DOR and low affinity for KOR. Using
our validated receptor models of the active and inactive states of
all three receptors for structure-based design, we were able to
achieve this goal by selectively modulating the affinity and efficacy
of our lead peptide 1. First, examination of docking of the lead
peptide, 1, to active state KOR suggested the participation of the
ligand's Phe4 residue in an aromatic p–p interaction unavailable in
MOR or DOR. Replacement of this Phe4 with an aliphatic residue
(peptides 2–4) achieved the desired result of greatly reducing KOR
affinity and efficacy. Next, predicted differences in ligand docking
to the DOR active and inactive conformations were exploited by
incorporating bulkier residues in the third position of peptide 1 to
favor binding to the DOR inactive conformation. As predicted, the
use of 1-Nal or 2-Nal in place of Phe3 greatly reduced DOR
Table 2: Binding Affinities and Efficacies of Peptides 6–15
Peptide Sequence
Ki (nM) Efficacy % standard
MOR DOR KOR MOR MOR EC50 (nM) DOR KOR
6 Tyr-c(S-S)[DCys-2Nal-Nle-Cys]NH2 2.4 € 1.3 240 € 70 1000 € 420 25 € 1 32 € 11 dns
7 Tyr-c(S-S)[DCys-2Nal-Nle-DCys]NH2 2.1 € 0.9 950 € 190 1400 € 500 9.3 € 0.9 dns dns
8 Tyr-c(S-S)[DCys-1Nal-Nle-Cys]NH2 0.65 € 0.3 12 € 2.7 730 € 330 100 € 2 5.1 € 1.4 22 € 0.9 <7
9 Tyr-c(S-S) [DCys-1Nal-Nle-DCys]NH2 1.4 € 0.3 56 € 2.5 1200 € 350 43 € 2.7 17.5 € 5.0 dns <5
10 Tyr-c(S-(CH2)2-S)[DCys-1Nal-Nle-Cys]NH2 1.3 € 0.1 37 € 1.5 180 € 90 51 € 6 8.3 € 1.3 24 € 1 <7
11 Tyr-c(S-(CH2)2-S) [DCys-1Nal-Nle-DCys]NH2 1.4 € 0.4 23 € 2.9 770 € 140 31 € 1.2 dns <7
12 Tyr-c(S-S) [DCys-1Nal-Nle-Cys]OH 3.7 € 2 11 € 3 5100 € 2600 94 € 1 3.4 € 0.8 17 € 2 30 € 8
13 Tyr-c(S-S) [DCys-1Nal-Nle-DCys]OH 2.7 € 0.3 4.0 € 0.5 5600 € 500 dns dns dns
14 Tyr-c(S-(CH2)2-S) [DCys-1Nal-Nle-Cys]OH 8.6 € 1.4 58 € 8.3 1300 € 100 47 € 4 35.5 € 5.0 11 € 8 nt
15 Tyr-c(S-(CH2)2-S) [DCys-1Nal-Nle-DCys]OH 3.1 € 0.04 29 € 4 1000 € 200 39 € 3.4 7.3 € 1.4 nt
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] diprenorphine. Efficacy data were obtained using [35S] GTPcS binding
assay. Efficacy is represented as per cent maximal stimulation relative to standard agonists DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 lM concen-
trations. EC50 values are provided for compounds displaying >40% maximal stimulation. All values are expressed as mean € SEM of three separate assays per-
formed in duplicate. Cyclization abbreviated as S-S for disulfide linkage and S-(CH2)2-S for ethylene dithioether, nt = not tested, dns = does not stimulate.
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efficacy. Analogs 8 and 12, in particular, with 1-Nal3, exhibited the
desired profile of high MOR ⁄ low DOR efficacy. The wide range of
affinity and efficacy shown by the closely related analogs in Table 2
reflects both the structural sensitivity of the ligand–receptor inter-
action and the utility of peptides, whose structures can be easily
and subtly manipulated for probing the details of the ligand–recep-
tor interaction. Of particular note is the profound functional differ-
ence observed for 12 and 13, which differ only in stereochemistry
of the C-terminal residue and which possess similar affinity, but
quite different efficacy profiles. The results reported here further
validate our receptor models and our approach of using these mod-
els for rational design to exploit differences in the opioid receptors
highly homologous binding pockets.
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